Novel Targeted Therapy, Immunotherapy, and Immune Biomarkers for Gastroesophageal and Liver Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (30 June 2024) | Viewed by 2436

Special Issue Editors


E-Mail Website
Guest Editor
Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Interests: gastric cancer; esophageal cancer; colon cancer; hepatocellular carcinoma; bile duct cancer
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Medical Oncology, Novant Health Cancer Institute, Charlotte, NC 28204, USA
Interests: developmental therapeutics; molecularly targeted agents; epigenetic modifiers; small molecule inhibitors; immune-oncology; bispecifics; T-cell engagers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Targeted therapy for cancer involves inhibiting tumor growth by disrupting essential chemical pathways or mutant proteins. Conversely, immunotherapy aims to provoke a host immune response, culminating in tumor destruction. These strategies manifest heightened efficacy within specific subsets of gastroesophageal cancer patients.

Gastroesophageal cancer, encompassing gastric and esophageal carcinomas along with gastroesophageal junction carcinoma, is a prevalent malignancy in the gastrointestinal realm. It ranks fourth and fifth globally in terms of incidence and mortality, respectively. Hepatocellular carcinoma (HCC) is one of the most common and lethal hepatic malignancies. The development of personalized regimens, including vaccine therapies and adoptive cell treatments, coupled with an intricate comprehension of immune response predictive biomarkers, holds promise for optimizing therapeutic outcomes.

This Special Issue is dedicated to shedding light on therapeutic advances for gastroesophageal cancer and HCC. It will encompass insights into novel standard and investigational treatment interventions involving targeted therapy and immunotherapy in this population. The emphasis is on research work highlighting or investigating potential prognostic and therapeutic predictive biomarkers of those novel therapeutics.

You may choose our Joint Special Issue in Current Oncology.

Dr. Anwaar Saeed
Dr. Ludimila Cavalcante
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunotherapy
  • targeted therapy
  • immune checkpoint inhibitors
  • gastroesophageal cancer
  • liver cancer
  • biomarkers

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

15 pages, 2668 KiB  
Review
Immunotherapy and Radiation Therapy Combinatorial Approaches in Hepatocellular Carcinoma
by Alireza Tojjari, James Yu and Anwaar Saeed
Cancers 2024, 16(5), 1058; https://doi.org/10.3390/cancers16051058 - 5 Mar 2024
Viewed by 2040
Abstract
Hepatocellular carcinoma (HCC), a prevalent and often fatal liver cancer, presents significant treatment challenges, especially in its advanced stages. This article delves into the promising approach of combining immunotherapy, particularly immune checkpoint inhibitors, with radiation therapy, a cornerstone of HCC management. Our review [...] Read more.
Hepatocellular carcinoma (HCC), a prevalent and often fatal liver cancer, presents significant treatment challenges, especially in its advanced stages. This article delves into the promising approach of combining immunotherapy, particularly immune checkpoint inhibitors, with radiation therapy, a cornerstone of HCC management. Our review synthesizes current preclinical and clinical research, highlighting the potential synergistic effects of this combinational treatment. Emerging evidence suggests that this synergy enhances tumor control and improves patient survival rates. The combination leverages the localized, tumor-targeting ability of radiation therapy and the systemic, immune-boosting effects of immunotherapy, potentially overcoming the limitations inherent in each treatment modality when used separately. This integrative approach is especially promising in addressing the complex tumor microenvironment of HCC. However, the treatment landscape is nuanced, with challenges such as patient-specific response variability and potential resistance to therapies. Future research directions should focus on refining these combination strategies, tailoring them to individual patient profiles, and understanding the underlying mechanisms that govern the interaction between immunotherapy and radiation therapy. Such advancements could significantly improve HCC management, setting new standards for patient care and treatment efficacy. Full article
Show Figures

Figure 1

Back to TopTop